MaxCyte
MXCT
103 hedge funds and large institutions have $687M invested in MaxCyte in 2021 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 42 increasing their positions, 16 reducing their positions, and 11 closing their positions.
218% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 11
163% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 16
29% more funds holding
Funds holding: 80 → 103 (+23)
12.51% more ownership
Funds ownership: 54.28% → 66.79% (+13%)
3% more capital invested
Capital invested by funds: $670M → $687M (+$17.4M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| 1 |
BlackRock
New York
|
+$48.7M |
| 2 |
BAMCO Inc
New York
|
+$37.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$13.1M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$10.6M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.1M |
Top Sellers
MXCT Hedge Fund Activity: Q4 2021 in Review
103 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in MaxCyte (MXCT) for Q4 2021, worth a combined $687M — up 2.6% from $670M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new MXCT positions and 11 closed out — a net gain of 24 holders — while 42 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $48.7M. The largest seller was Montanaro Asset Management, cutting an estimated $12.6M.
- 103 institutional investors held MaxCyte (MXCT) as of Q4 2021, up from 80 in Q3 2021.
- Funds reported $687M of MaxCyte stock for Q4 2021, up 2.6% quarter-over-quarter.
- 35 funds opened new MaxCyte positions in Q4 2021 and 11 closed out, a net change of +24 holders.
- The largest MaxCyte buyer in Q4 2021 was BlackRock, an estimated $48.7M added.
- The largest MaxCyte seller in Q4 2021 was Montanaro Asset Management, an estimated $12.6M sold.
Based on aggregated 13F filings for Q4 2021.